VIP	vasoreactive intestinal polypeptide
PACAP	pituitary adenylate cyclase-activating polypeptide
COX	cyclooxygenase
PTGES	PGE synthase
IRF3	interferon regulatory factor 3
TBK1	TANK-binding kinase 1
TNF	tumor necrosis factor
NF-κB	nuclear factor kappa-B
STAT	signal transducers and activator of transcription
MPL	monophosphoryl lipid A

REFERENCES

[1] Akira S. Innate immunity and adjuvants. Phil Trans R Soc B 2011;366:2748-2755.

[2] Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291-295.

[3] Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev 2010;234:317-334.

[4] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.

[5] Elinav E, Strowig T, Henao-Mejia J, Flavell Richard A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011;34:665-679.

[6] Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011;34:680-692.

[7] Osorio F, Reis e Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011;34:651-664.

[8] Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012;12:479-491.

[9] Lambrecht BN, Kool M, Willart MAM, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-29.

[10] O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59—an innately attractive adjuvant formulation. Vaccine 2012;30:4341-4348.

[11] Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998;32:155-172.

[12] Aimanianda V, Haensler J, Lacroix-Desmazes S, et al. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 2009;30:287-295.

[13] Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9:287-293.

[14] Mancino D, Buono G, Cusano M, Minucci M. Adjuvant effects of a crystalline silica on IgE and IgG1 antibody production in mice and their prevention by the macrophage stabilizer poly-2-vinylpyridine N-oxide. Int Arch Allergy Appl Immunol 1983;71:279-281.

[15] Sharp FA, Ruane D, Claass B, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci USA 2009;106:870-875.

[16] Nygaard UC, Aase A, Lovik M. The allergy adjuvant effect of particles—genetic factors influence antibody and cytokine responses. BMC Immunol 2005;6:11.

[17] Kuroda E, Ishii KJ, Uematsu S, et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011;34:514-526.

[18] Inoue K, Koike E, Yanagisawa R, et al. Effects of multi-walled carbon nanotubes on a murine allergic airway inflammation model. Toxicol Appl Pharmacol 2009;237:306-316.

[19] Nygaard UC, Hansen JS, Samuelsen M, et al. Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. Toxicol Sci 2009;109:113-123.

[20] Ichinose T, Takano H, Miyabara Y, et al. Murine strain differences in allergic airway inflammation and immunoglobulin production by a combination of antigen and diesel exhaust particles. Toxicology 1997;122:183-192.

[21] Lovik M, Hogseth AK, Gaarder PI, et al. Diesel exhaust particles and carbon black have adjuvant activity on the local lymph node response and systemic IgE production to ovalbumin. Toxicology 1997;121:165-178.

[22] Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-882.

[23] Behrens MD, Wagner WM, Krco CJ, et al. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008;111:1472-1479.

[24] Willart MAM, Lambrecht BN. The danger within: endogenous danger signals, atopy and asthma. Clin Exp Allergy 2009;39:12–19.

[25] Kool M, Willart Monique AM, van Nimwegen M, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011;34:527–540.

[26] Kool M, Hammad H, Lambrecht B. Cellular networks controlling Th2 polarization in allergy and immunity. F1000 Biol Rep 2012;4:6.

[27] Coban C, Igari Y, Yagi M, et al.. Immunogenicity of whole-parasite vaccines against *Plasmodium falciparum* involves malarial hemozoin and host TLR9. Cell Host Microbe 2010;7:50–61.

[28] Reese TA, Liang H-E, Tager AM, et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 2007;447:92–96.

[29] Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847–856.

[30] Coban C, Yagi M, Ohata K, et al. The malarial metabolite hemozoin and its potential use as a vaccine adjuvant. Allergol Int 2010;59:115–124.

[31] Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes XVLL-XXIV. J Pathol Bacteriol 1926;29(1):31–40.

[32] Harrison WT. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health 1935;25:298–300.

[33] Holt LB. Developments in diphtheria prophylaxis. London: Heinemann; 1950.p. xvi; 181.

[34] Hutchison S, Benson RA, Gibson VB, et al. Antigen depot is not required for alum adjuvanticity. FASEB J 2011;26:1272–1279.

[35] Jordan MB. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004;304(5678):1808–1810.

[36] Wang HB, Weller PF. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol 2008;83:817–821.

[37] McKee AS, Munks MW, MacLeod MKL, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act As an adjuvant for specific immunity. J Immunol 2009;183:4403–4414.

[38] Ohnmacht C, Schwartz C, Panzer M, et al. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity 2010;33:364–374.

[39] Shah HB, Devera TS, Rampuria P, et al. Type II NKT cells facilitate alum-sensing and humoral immunity. J Leukoc Biol 2012;92:883–893.

[40] Brewer JM, Conacher M, Satoskar A, et al. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062–2066.

[41] Brewer JM, Conacher M, Hunter CA, et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999;163:6448–6454.

[42] Al-Shami A, Spolski R, Kelly J, et al. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005;202:829–839.

[43] Chen ZG, Zhang TT, Li HT, et al. Neutralization of TSLP inhibits airway remodeling in a murine model of allergic asthma induced by chronic exposure to house dust mite. PLoS ONE 2013;8:e51268.

[44] Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol 2012;129:1048–1055e6.

[45] Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947–950.

[46] Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006;314:1936–1938.

[47] Da Silva CA, Pochard P, Lee CG, Elias JA. Chitin particles are multifaceted immune adjuvants. Am J Respir Crit Care Med 2010;182:1482–1491.

[48] Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122–1126.

[49] Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674–677.

[50] Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–241.

[51] Tiemi Shio M, Eisenbarth SC, Savaria M, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathol 2009;5:e1000559.

[52] Dostert C, Guarda G, Romero JF, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS ONE 2009;4:e6510.

[53] Griffith JW, Sun T, McIntosh MT, Bucala R. Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol 2009;183:5208–5220.

[54] Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008;181:17–21.

[55] Kool M, Petrilli V, De Smedt T, et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008;181:3755–3759.

[56] Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur J Immunol 2008;38:2085–2089.

[57] Pollock KG, Conacher M, Wei XQ, et al. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology 2003;108:137–143.

[58] Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516–521.

[59] Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010;233:203–217.

[60] Mócsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387–402.

[61] Ng G, Sharma K, Ward SM, et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008;29:807–818.

[62] Flach TL, Ng G, Hari A, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011;17:479–487.

[63] Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice. J Mol Med (Berlin) 2009;87:1015–1022.

[64] Fabricius D, Neubauer M, Mandel B, et al. Prostaglandin E2 inhibits IFN-alpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol 2010;184:677–684.

[65] Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 2003;170:757–764.

[66] Koga K, Takaesu G, Yoshida R, et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009;30:372–383.

[67] Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 2009;206:535–548.

[68] Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009;15:633–640.

[69] Uematsu S, Matsumoto M, Takeda K, Akira S. Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/MyD88/NF-IL6 pathway. J Immunol 2002;168:5811–5816.

[70] Fedyk ER, Phipps RP. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci USA 1996;93:10978–10983.

[71] Roper RL, Brown DM, Phipps RP. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J Immunol 1995;154:162–170.

[72] Delgado M, Leceta J, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol 1999;163:3629–3635.

[73] Delgado M, Gomariz RP, Ganea D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 2004;18:1453–1455.

[74] Traidl-Hoffmann C, Mariani V, Hochrein H, et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005;201:627–636.

[75] Mariani V, Gilles S, Jakob T, et al. Immunomodulatory mediators from pollen enhance the migratory capacity of dendritic cells and license them for Th2 attraction. J Immunol 2007;178:7623–7631.

[76] Marichal T, Ohata K, Bedoret D, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011;17:996–1002.

[77] Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007;28:33–38.

[78] Robinson RT, Khader SA, Locksley RM, et al. Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J Immunol 2008;181:5560–5567.

[79] Nagel J, Svec D, Waters T, Fireman P. IgE synthesis in man. I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J Immunol 1977;118:334–341.

[80] Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497–505.

Role of extrachromosomal histone H2B on recognition of DNA viruses and cell damage

Kouji Kobiyama[1,2], Akira Kawashima[3,4], Nao Jounai[1,2], Fumihiko Takeshita[1,2], Ken J. Ishii[1,2], Tetsuhide Ito[5] and Koichi Suzuki[3]*

[1] Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan
[2] Laboratory of Vaccine Science, Immunology Frontier Research Center, World Premier International Research Center, Osaka University, Suita, Osaka, Japan
[3] Laboratory of Molecular Diagnostics, Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan
[4] Division of Bioimaging Sciences, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan
[5] Department of Medicine and Bioregulatory Science, Kyushu University, Fukuoka, Japan

Histones are essential components of chromatin structure, and histone modification plays an important role in various cellular functions including transcription, gene silencing, and immunity. Histones also play distinct roles in extrachromosomal settings. Extrachromosomal histone H2B acts as a cytosolic sensor to detect double-stranded DNA (dsDNA) fragments derived from infectious agents or damaged cells to activate innate and acquired immune responses in various cell types. It also physically interacts with interferon (IFN)-β promoter stimulator 1 (IPS-1), an essential adaptor molecule that activates innate immunity, through COOH-terminal importin 9-related adaptor organizing histone H2B and IPS-1 (CIAO), resulting in a distinct signaling complex that induces dsDNA-induced type I IFN production. Such a molecular platform acts as a cellular sensor to recognize aberrant dsDNA in cases of viral infection and cell damage. This mechanism may also play roles in autoimmunity, transplantation rejection, gene-mediated vaccines, and other therapeutic applications.

Keywords: DNA sensor, extrachromosomal histone, virus infection, DNA damage, epigenetic modifications

INTRODUCTION

Epigenetic modifications of histones, the primary protein component of chromatin, contribute to diverse homeostatic cellular activities such as transcriptional regulation, chromosome condensation (mitosis), apoptosis, and DNA repair (Bradbury, 1992; Koshland and Strunnikov, 1996; Rogakou et al., 2000; Fernandez-Capetillo et al., 2004). Histones are divided into two groups based on their principal functions. Histones H2A, H2B, H3, and H4 are known as the core histones. Two of each core histone form the histone octamer, which genomic DNA wraps around to form a nucleosome (Luger et al., 1997). Histone H1, the linker histone, binds and rearranges the DNA between nucleosome units (linker DNA) to assist chromatin compaction. Interestingly, histones are present in cytosol (Kobiyama et al., 2010) as well as in the nucleus, mitochondria (Konishi et al., 2003), and cell surface (Radic et al., 2004), particularly during viral infections, apoptosis, and cell damage. Histone H2B transits in and out of the nucleosome more rapidly than other core histones, such as H3 and H4. Thus, about 3% of total H2B is exchanged within 6 min ($t_{1/2}$), ~40% within 130 min, and ~50% by 8.5 h (Kimura, 2005). Histones have microbicidal activity in neutrophil extracellular traps (NETs), which are composed of DNA, elastase, and histones. Treatment of NETs with histone neutralizing antibodies resulted in reduced bactericidal activity against species such as *Shigella flexneri* and *Staphylococus aureus* (Brinkmann et al., 2004). Thus, these "extrachromosomal" histones play important roles in physiological conditions,

including innate and adaptive immune responses. We recently reported that extrachromosomal histone H2B is involved in the recognition of cytosolic double-stranded DNA (dsDNA) generated by DNA viruses (non-self) and genomic DNA from damaged cells (self) (Kobiyama et al., 2010; Kawashima et al., 2011a).

DNA-MEDIATED IMMUNE RESPONSE

In 1963, Alick Isaacs found that nucleic acids, both DNA and RNA, strongly induce innate immune responses, such as type I interferon (IFN) production (Isaacs et al., 1963; Rotem et al., 1963). Although this finding generated a great deal of excitement in the field of immunology at that time, it was forgotten or largely ignored until it was shown that unmethylated CpG DNA stimulates immune cells to produce cytokines (Tokunaga et al., 1984; Krieg et al., 1995). As a result, most immunologists presumed that unmethylated CpG DNA was the essential element within self and non-self DNA that activated innate immunity. Toll-like receptor 9 (TLR9) was subsequently identified as a cellular receptor for unmethylated CpG DNA in the activation of innate immune responses in immune cells, such as dendritic cells (DCs), B cells, and macrophages (Hemmi et al., 2000, 2003). In the meantime, dsDNA independent of unmethylated CpG motifs or any other specific sequence was shown to up-regulate the expression of genes related to the immune response (Suzuki et al., 1999). In particular, genomic dsDNA released by injured cells induces maturation of antigen presenting cells and adaptive immune responses (Ishii et al., 2001).

Furthermore, TLR9-dependent and -independent IFN-α production is induced in response to herpes simplex virus-1 (HSV-1) infection (Hochrein et al., 2004). It was later confirmed that the right-handed helical structure (B-form) of DNA is the component responsible for induction of robust type I IFNs in both immune and non-immune cells through TLR9-independent recognition and signaling cascades (Ishii et al., 2006; Stetson and Medzhitov, 2006).

The harmful effects of aberrant DNA have been shown in relation to the function of enzymes that digest DNA (DNases). Thus, hepatic macrophages in DNase II-deficient mice failed to digest DNA from engulfed nuclei of erythroblasts and exhibited robust production of type I IFN, which resulted in severe anemia and development of rheumatoid arthritis (RA)-like symptoms in a TLR9-independent manner (Yoshida et al., 2005; Kawane et al., 2006). DNase I and DNase III knockout mice showed systemic lupus erythematosus (SLE)-like symptoms and inflammatory myocarditis, respectively (Napirei et al., 2000; Yasutomo et al., 2001; Morita et al., 2004). The functional mutations of DNase I and DNase III in humans have also been associated with several autoimmune disorders, such as SLE (Yasutomo et al., 2001; Lee-Kirsch et al., 2007b), Aicardi–Goutieres syndrome (Crow et al., 2006), familial chilblain lupus (Lee-Kirsch et al., 2007a), and retinal vasculopathy with cerebral leukodystrophy (Richards et al., 2007). Thus, DNA-induced immune responses are involved in the prevention of both microbial infection and autoimmune responses. These findings also suggest that normal cells are equipped with innate machinery that senses and removes aberrant genomic DNA fragments before they produce pathological effects.

CYTOSOLIC SENSORS FOR DNA FRAGMENTS AND THEIR METABOLITES

Several proteins have been identified as DNA sensors that recognize aberrant cytosolic DNA fragments and their metabolites. These sensors are involved in the elimination of invasive pathogens and the induction of inflammation. In most cases, recognition of cytosolic DNA by these sensors results in induction of innate immune responses through several key proteins such as stimulator of interferon genes (STING) and TANK-binding kinase 1 (TBK1) (Ishii et al., 2006; Ishikawa and Barber, 2008). STING and TBK1 are also essential factors in the immunogenicity of plasmid DNA vaccines (Ishii et al., 2008; Ishikawa et al., 2009). The underlying mechanisms for the immunological advantages of DNA vaccines have not been fully elucidated. However, it has been suggested that the detection of the double-stranded structure of plasmid DNA by cytosolic DNA sensors contributes to an enhanced adaptive immune response to the vaccine antigen.

Z-DNA binding protein 1/DNA-dependent activator of IFN-regulatory factors (ZBP-1/DAI) was the first reported cytosolic DNA sensor (Takaoka et al., 2007). ZBP-1/DAI contains two Z-DNA binding domains and a D3 domain, all of which are essential for its activation. Overexpression of ZBP-1/DAI enhanced dsDNA-mediated gene expression and knockdown of ZBP-1/DAI impaired IFN-β production by HSV-1 infection, but not Newcastle disease virus (NDV) infection, in a mouse fibroblast cell line (Takaoka et al., 2007). However, fibroblasts from ZBP-1/DAI deficient mice

normally responded to dsDNA, and the mice also showed normal immunogenicity to plasmid DNA vaccinations (Ishii et al., 2008).

In 1993, it was reported that electroporated DNA induces cell death in murine macrophages (Stacey et al., 1993). Recently, absence in melanoma 2 (AIM2) was identified as a cytosolic DNA sensor for activation of the inflammasome, a large multimolecular complex that regulates activation of the enzyme caspase-1, to induce IL-1β production and DNA-induced cell death. AIM2 is a member of the hematopoietic IFN-inducible nuclear protein with a 200-amino-acid repeat (HIN-200) family, which contains a pyrin domain and a DNA-binding HIN-200 domain. AIM2 recognizes cytosolic DNA and interacts with inflammasome-related molecules to induce pyroptosis, a type of programed cell death characterized by activation of caspase-1 and IL-1β production upon inflammatory antimicrobial responses. Deficiency of AIM2 results in an enhancement of susceptibility to bacteria and DNA viruses (Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Roberts et al., 2009).

Interferon gamma inducible protein 16 (IFI16) is a member of the pyrin and HIN domain-containing (PYHIN) protein family that contains a pyrin domain and two DNA-binding HIN domains. IFI16 directly binds viral DNA in the cytosol and induces IFN-β production through STING (Unterholzner et al., 2010). Small interfering RNA (siRNA) for IFI16 inhibited DNA-induced but not RNA-induced IFN-β production. Knockdown of p204, a mouse ortholog of IFI16, impaired activation of transcription factors and gene inductions upon DNA virus infection.

Although retinoic acid-inducible gene I (RIG-I) was initially identified as a cytosolic RNA receptor, it is also involved in the recognition of cytosolic dsDNA. Thus, knockdown of RIG-I in human hepatocellular carcinoma cell line, HuH-7, attenuated dsDNA-induced type I IFN production. Subsequently, it was shown that poly(dA·dT)·poly(dT·dA) and DNA virus-derived DNAs were converted into 5′-triphosphate RNA by RNA polymerase III to induce RIG-I-mediated type I IFN production. This IFN production induced by intracellular bacteria was abolished by a specific inhibitor of RNA polymerase III, which in turn resulted in a promotion of bacterial growth (Chiu et al., 2009).

High mobility group box protein 1 (HMGB1), initially identified as a non-histone DNA-binding and chromatin-associated protein, is involved in DNA organization and transcriptional regulation (Goodwin et al., 1973; Bustin, 1999). Although most of HMGB1 is localized to the nucleus, HMGB1 acts as an "alarmin" to promote inflammation upon its release from the nucleus during necrosis (Scaffidi et al., 2002). In addition, extracellular HMGB1 is involved in the pathogenesis of autoimmune diseases, as evidenced by the presence of anti-HMGB1 autoantibodies in sera from RA and drug-induced SLE patients (Wittemann et al., 1990; Ayer et al., 1994). The HMGBs (HMGB1, HMGB2, and HMGB3) also bind immunogenic nucleic acids, e.g., virus-derived RNAs and genomic DNAs, and activate innate immune signaling through receptor for advanced glycation and end products (RAGE). In fact, knockdown of HMGBs resulted in a reduction of innate immune responses against immunogenic nucleic acids (Yanai et al., 2009).

In human cells, various types of DNA reportedly induce type III IFNs, especially IFN-λ1 (or interleukin29; IL29). Ku70,

whose original functions were reported as DNA repair, V(D)J recombination and telomerase maintenance, was identified as a cytosolic DNA sensor that is responsible for the induction of IFN-λ1 (Zhang et al., 2011a). Knockdown of Ku70 suppressed IFN-λ1 activation in human cells. Whereas other known DNA sensors are involved in type I IFN production, Ku70 is unique in the production of type III IFN upon dsDNA stimulation.

Leucine-rich repeat flightless-interacting protein 1 (LRRFIP1) was initially identified as an RNA-binding protein, but it was eventually recognized as a receptor for both exogenous DNA and RNA (Yang et al., 2010). LRRFIP contains a DNA-binding domain, and is responsible for the production of IFN-β through interaction with β-catenin and recruitment of acetyltransferase p300 in cases of vesicular stomatitis virus (VSV) and *Listeria monocytogenes* infection.

RNA and DNA helicases are members of the DEADbox family, the name of which was derived from one of the conserved amino-acid sequences in the proteins. Members of the DExD/H-box (where x can be any amino acid) helicase superfamily, such as DHX9 and DHX36, were identified as cytosolic CpG DNA sensors for the induction of type I IFN production in plasmacytoid DCs (Kim et al., 2010). Another helicase, DDX41, a member of the DEXDc family, was identified as an intracellular dsDNA sensor that is responsible for type I IFN production in myeloid DCs (Zhang et al., 2011b). After stimulation with dsDNA, DDX41 interacts with STING in the microsome, mitochondria, and mitochondria-associated endoplasmic reticulum membrane fractions. DDX41 also recognizes bacterial second messenger cyclic di-GMP and cyclic di-AMP, and activates type I IFN production by interacting with STING, leading to TBK1-IRF3 activation (Parvatiyar et al., 2012).

DNA transfection or DNA virus infection leads to a production of cyclic GMP-AMP (cGAMP) via the function of cGAMP synthase, cGAS, which belongs to the nucleotidyltransferase family, and an endogenous second messenger to induce innate immune responses. cGAS binds to DNA in the cytoplasm and catalyzes cGAMP synthesis to function as a cytosolic dsDNA sensor that induces type I IFNs (Sun et al., 2013). It was also shown that cGAMP directly interacts with STING to activate IRF3, and knockdown of cGAS results in the suppression of IFN-β production induced by dsDNA transfection or DNA virus infection (Sun et al., 2013).

These studies were performed using different types of cells, synthetic DNAs, bacteria, and viruses as shown in **Table 1**. Therefore, it should be noted that multiple recognition machineries for sensing cytosolic DNA and DNA metabolites might differ among species and/or cell types.

EXTRACHROMOSOMAL HISTONE H2B IS INVOLVED IN DNA SENSING

To identify molecules responsible for cytosolic dsDNA-mediated type I IFN production, we screened a cDNA expression library using HEK293T cells stably transfected with a luciferase gene cassette under an IFN-β promoter. Among >960,000 independent clones examined, a single clone encompassing the histone H2B ORF exhibited a striking enhancement of dsDNA-induced IFN-β promoter activation (Kobiyama et al., 2010). In a separate set of experiments, cellular proteins that bind dsDNA were purified from rat thyroid cell line FRTL-5, cells previously proven to respond well to dsDNA (Suzuki et al., 1999). Protein extracts were passed through ssDNA sepharose and absorbed onto dsDNA sepharose columns before electrospray ionization (ESI)-MS/MS mass spectrometry analysis. Among the molecules identified, histone H2B showed a significantly high MASCOT (probability) score (Kawashima et al., 2011a). Thus, two independent approaches implied that extrachromosomal H2B functionally mediates IFN-β promoter activation in human kidney cells following dsDNA stimulation and physically associates with dsDNA in rat thyroid cells.

Type I IFN production induced by dsDNA was significantly suppressed in HEK293 cells treated with H2B siRNA, but not by those treated with siRNAs for other core histones. Although most histone H2B localizes in the nucleus, it appears to sense DNA in the cytoplasm by interacting with IFN-β promoter stimulator 1 (IPS-1) (Kobiyama et al., 2010), an essential adaptor molecule for signal activation triggered by cytoplasmic dsRNA and single stranded 5′-triphosphate RNA (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). Human, but not mouse, IPS-1 was involved in the dsDNA-mediated signal transduction (Kumar et al., 2006; Ishii et al., 2008). Therefore, histone H2B interacts with IPS-1 in the cytoplasm following dsDNA stimulation only in human cells.

Yeast two-hybrid screening identified KIAA1192 as a molecule that interacts directly with histone H2B; therefore, it was renamed CIAO (C-terminal importin 9-related adaptor organizing histone H2B and IPS-1) based on its novel role. While high similarities of amino acid sequences were detected between human and mouse H2B (>70.1%) and between human and mouse CIAO (99.2%), the amino acid sequence of IPS-1 was largely different between human and mouse (30.3%). The observed interaction of CIAO and IPS-1 only in human molecules is a possible reflection of this difference in IPS-1 sequence (Kobiyama et al., 2010). These results strongly suggest that there is species-specific involvement of IPS-1 in dsDNA-mediated signaling.

We further examined the role of histone H2B on cell-autonomous antiviral responses. Knockdown of histone H2B suppressed IFN-β production and STAT1 phosphorylation when DNA viruses, in this case modified vaccinia virus Ankara (MVA), were infected (Kobiyama et al., 2010). Multiplication of adenovirus type 5 was significantly enhanced in the H2B knockdown cells, while multiplication of RNA viruses, such as encephalomyocarditis virus (EMCV), was not affected by the presence or absence of histone H2B (**Figure 1A**). Multiplication of other DNA viruses, such as human papilloma viruses (HPV11 and HPV16) and adenovirus serotype 5, was significantly enhanced in cells to which histone H2B siRNA was transfected. These results suggested that extrachromosomal histone H2B is involved in the sensing of DNA viruses and mediates cell-autonomous antiviral immune responses in human cells. The human immunodeficiency virus (HIV) is a lentivirus, a class of retrovirus, which has two copies of positive single stranded RNA that codes viral genes. Upon infection in target cells, the viral RNA genome is reverse transcribed into dsDNA in the peri-integration complex (PIC). When

Table 1 | Cytosolic DNA sensors.

| DNA sensor	Localization	Pathogens	Nucleic acid ligand	Reference
ZBP-1/DAI	Cytoplasm	HSV	Poly(dA:dT), ISD	Takaoka et al. (2007)
AIM2	Cytoplasm	VV, MCMV, L. monocytogenes, F. tularensis	Calf thymus DNA, poly(dA:dT)	Burckstummer et al. (2009), Fernandes-Alnemri et al. (2009), Hornung et al. (2009), Roberts et al. (2009)
IFI16	Cytoplasm	VV, HSV-1	Poly(dA:dT)	Unterholzner et al. (2010)
RNA pol III/RIG-I	Cytoplasm	L. pneumophila, AdV, HSV-1, EBV	Poly(dA:dT)	Chiu et al. (2009)
HMGB1	Nucleus, extracellular	VSV, HSV-1	dsDNA, dsRNA, ssDNA, ssRNA	Yanai et al. (2009)
Ku70	Cytoplasm	HIV?	Plasmid DNA	Zhang et al. (2011a)
LRRFIP1	Cytoplasm	L. monocytogenes, VSV	Poly(dA:dT)	Yang et al. (2010)
DDX41	Cytoplasm	L. monocytogenes, AdV, HSV-1, VV	Poly(dA:dT), c-d-GMP, c-d-AMP	Zhang et al. (2011b), Parvatiyar et al. (2012)
cGAS	Cytoplasm	HSV-1	cGAMP	Sun et al. (2013)
Histone H2B	Nucleus, cytoplasm	HPV, AdV, HIV	Poly(dA:dT), genomic DNA	Kobiyama et al. (2010), Kawashima et al. (2011a)

HSV, herpes simplex virus; VV, vaccinia virus; MCMV, mouse cytomegalovirus; AdV, adenovirus; EBV, Epstein–Barr virus; VSV, vesicular stomatitis virus; HIV, human immunodeficiency virus; HPV, human papilloma virus; dA:dT, poly(dA-dT)·poly(dT-dA); ISD, immunostimulatory DNA.

FIGURE 1 | Histone H2B is a key factor for the suppression of viral replication. (A) HEK293 and HeLa cells were pretreated with control siRNA (Cont siRNA) or histone H2B siRNA (H2B siRNA). The cells were infected with AdV type 5 or EMCV. Twenty-four hours after infection, viral multiplication was determined by a plaque assay. (B) Magic 5 cells were pretreated with Cont siRNA or H2B siRNA. The cells were infected with HIV-1 IIIB for 3 h. Seventy-four hours after infection, viral multiplication was determined by HIV-1 p24 ELISA using culture supernatant.

histone H2B was knocked-down in CCR5-expressing HeLa/CD4$^+$ cell clone 1–10 (Magic 5) cells, HIV-1 replication was significantly enhanced (**Figure 1B**). These data clearly indicate that histone H2B discriminates between foreign DNA and RNA upon viral infection to evoke IPS-1-mediated signaling through association with a novel adaptor protein, CIAO. It has also been suggested that human IPS-1 has evolutionarily gained the potential to transmit dsDNA-initiated, histone H2B-mediated signaling to combat human viruses that produce DNA intermediates within the cell. Whether histone H2B has a role in infection in mice, probably by interacting with molecules other than IPS-1, is currently unknown.

We next examined the involvement of genomic DNA-mediated immune responses in light of a possible role in the triggering of autoimmune disorders. When FRTL-5 thyroid cells were exposed to progressively higher levels of electric pulsing, in the absence of pathogens or immune cells, genomic DNA was released to the cytoplasm, which was associated with activation of the expression of certain genes, such as those encoding type I IFN and chemokines.

More importantly, the expression of major histocompatibility complex (MHC) class II molecules and co-stimulatory molecules was also induced in thyroid cells (Suzuki et al., 1999; Kawashima et al., 2011a), suggesting that the autoimmune target cell itself might present autoantigens upon cell damage (Kawashima et al., 2011b). It has been assumed that autoimmune thyroid diseases, such as Graves's disease and Hashimoto's thyroiditis, develop by a combination of genetic susceptibility and environmental factors. The data suggested that thyroid cell injury results in the release of genomic DNA fragments into the cytosol, which are recognized by extrachromosomal histone H2B to activate genes involved in both innate and acquired immune responses. Such responses may relate to the development of thyroiditis that in turn may increase the chance to present self-antigens to immune cells and initiate autoimmune reactions. Thus, our findings suggest that extrachromosomal histone H2B acts as a cytosolic DNA sensor for both self and non-self DNA, and that this recognition mechanism may be involved in preventing microbial infections and triggering of autoimmune disorders.

FIGURE 2 | Mode of extrachromosomal histone H2B-mediated innate immune responses. Under normal conditions, histone H2B primarily localizes to the nucleus. In cases of cell damage or viral infection, histone H2B recognizes aberrant self- or non-self-derived dsDNA and forms an H2B-CIAO-IPS-1 interaction complex in the cytoplasm, which in turn activates TBK1 and induces IRF3 phosphorylation to produce type I IFN.

EPIGENETIC MODIFICATION AND VIRUS INFECTION

Epigenetic modifications, including histone modifications and chromatin remodeling, regulate cellular processes that require access to genomic DNA. DNA viruses utilize the chromatin-mediated regulation of gene transcription and DNA replication of the host cell (Liang et al., 2009). In the case of herpes viruses, chromatin modulation is a regulatory factor of viral latency and reactivation cycles. Infection of cells with herpes virus results in the deposition of nucleosomes bearing repressive K9 methylation of histone H3 (H3-K9) on the viral genome. Inhibition of lysine-specific demethylase (LSD1) results in an accumulation of repressive chromatin and blockage of viral gene expression (Liang et al., 2009). In the case of HIV-1, histone H3-K9 methyltransferase G9a is responsible for chromatin-mediated HIV-1 transcriptional latency through methylation of H3 (Imai et al., 2010). In addition, K9 methylation of histone H3 is involved in repression of the human cytomegalovirus gene (Ioudinkova et al., 2006). Thus, since viruses utilize the host gene regulation system for their replication, its modification blocks initial gene expression of a DNA virus, including adenovirus (Liang et al., 2013).

Histone H2B can also be modified by acetylation (Schiltz et al., 1999), GlcNAcylation (Fujiki et al., 2011), phosphorylation (Fernandez-Capetillo et al., 2004), sumoylation (Nathan et al., 2006), and ubiquitination (Zhu et al., 2005), but not by citrullination and methylation. Thus, histone H2B acetylation (K12 and K15) is involved in transcriptional activation (Schiltz et al., 1999; Kawasaki et al., 2000), and phosphorylation of histone H2B (S14) is an epigenetic marker of apoptotic cells (Cheung et al., 2003).

Deacetylation of K15 is essential for H2B S14 phosphorylation, and inhibition of deacetylation suppresses internucleosomal DNA degradation (Ajiro et al., 2010). Histone H2B is phosphorylated by irradiation, which accumulates in irradiation-induced foci (Fernandez-Capetillo et al., 2004). Ubiquitination of histone H2B is involved in DNA breaks (Wu et al., 2009). Since our findings suggest that histone H2B was involved in the recognition of both virus- and host-derived DNA, modification of histone H2B may also affect immune responses.

CONCLUDING REMARKS

It was long believed that the sole function of histones is to wrap genomic DNA for nucleosome assemblage. However, recent studies suggest a potential role for histones in other physiological functions in extrachromosomal settings. Histone H2A.X is phosphorylated in response to dsDNA breaks and recruited to the site of the break (Redon et al., 2002). Histone H3.3 accumulates in condensed chromatin where gene transcription is activated (Janicki et al., 2004). Also, histone H1.2 is a cytochrome c-releasing factor that appears in the cytoplasm after exposure to X-ray-irradiation (Konishi et al., 2003). More striking evidence is that extracellular histones have a cytotoxic ability and act as major mediators of death in cases of sepsis (Xu et al., 2009). In addition, human histone H2A and H2B have microbicidal activity, and are involved in killing promastigotes of Leishmania amazonensis (L. amazonensis), L. major, L. braziliensis, and L. mexicana. Exposure to histones markedly decreased the infectivity of promastigotes in murine macrophages in vitro (Wang et al., 2011). These data strongly suggest that extrachromosomal and extracellular histones

work as an alarmin to maintain cellular homeostasis by changing their modifications and subcellular localizations. Thus, extrachromosomal histone H2B acts as a sensor for dsDNA aberrantly present within the cell, alerting cells to dangerous situations, such as infection, apoptosis, DNA breaks, and cell injury (**Figure 2**). This mechanism may also play an important role in autoimmunity, transplantation rejection, gene-mediated vaccines, and other therapeutic applications.

REFERENCES

Ajiro, K., Scoltock, A. B., Smith, L. K., Ashasima, M., and Cidlowski, J. A. (2010). Reciprocal epigenetic modification of histone H2B occurs in chromatin during apoptosis in vitro and in vivo. *Cell Death Differ.* 17, 984–993.

Ayer, L. M., Rubin, R. L., Dixon, G. H., and Fritzler, M. J. (1994). Antibodies to HMG proteins in patients with drug-induced autoimmunity. *Arthritis Rheum.* 37, 98–103.

Bradbury, E. M. (1992). Reversible histone modifications and the chromosome cell cycle. *Bioessays* 14, 9–16.

Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., et al. (2004). Neutrophil extracellular traps kill bacteria. *Science* 303, 1532–1535.

Burckstummer, T., Baumann, C., Bluml, S., Dixit, E., Durnberger, G., Jahn, H., et al. (2009). An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. *Nat. Immunol.* 10, 266–272.

Bustin, M. (1999). Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. *Mol. Cell. Biol.* 19, 5237–5246.

Cheung, W. L., Ajiro, K., Samejima, K., Kloc, M., Cheung, P., Mizzen, C. A., et al. (2003). Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. *Cell* 113, 507–517.

Chiu, Y. H., Macmillan, J. B., and Chen, Z. J. (2009). RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. *Cell* 138, 576–591.

Crow, Y. J., Hayward, B. E., Parmar, R., Robins, P., Leitch, A., Ali, M., et al. (2006). Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. *Nat. Genet.* 38, 917–920.

Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J., and Alnemri, E. S. (2009). AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. *Nature* 458, 509–513.

Fernandez-Capetillo, O., Allis, C. D., and Nussenzweig, A. (2004). Phosphorylation of histone H2B at DNA double-strand breaks. *J. Exp. Med.* 199, 1671–1677.

Fujiki, R., Hashiba, W., Sekine, H., Yokoyama, A., Chikanishi, T., Ito, S., et al. (2011). GlcNAcylation of histone H2B facilitates its monoubiquitination. *Nature* 480, 557–560.

Goodwin, G. H., Sanders, C., and Johns, E. W. (1973). A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. *Eur. J. Biochem.* 38, 14–19.

Hemmi, H., Kaisho, T., Takeda, K., and Akira, S. (2003). The roles of toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. *J. Immunol.* 170, 3059–3064.

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., et al. (2000). A toll-like receptor recognizes bacterial DNA. *Nature* 408, 740–745.

Hochrein, H., Schlatter, B., O'keeffe, M., Wagner, C., Schmitz, F., Schiemann, M., et al. (2004). Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. *Proc. Natl. Acad. Sci. U.S.A.* 101, 11416–11421.

Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., et al. (2009). AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. *Nature* 458, 514–518.

Imai, K., Togami, H., and Okamoto, T. (2010). Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. *J. Biol. Chem.* 285, 16538–16545.

Ioudinkova, E., Arcangeletti, M. C., Rynditch, A., De Conto, F., Motta, F., Covan, S., et al. (2006). Control of human cytomegalovirus gene expression by differential histone modifications during lytic and latent infection of a monocytic cell line. *Gene* 384, 120–128.

Isaacs, A., Cox, R. A., and Rotem, Z. (1963). Foreign nucleic acids as the stimulus to make interferon. *Lancet* 2, 113–116.

Ishii, K. J., Coban, C., Kato, H., Takahashi, K., Torii, Y., Takeshita, F., et al. (2006). A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. *Nat. Immunol.* 7, 40–48.

Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., et al. (2008). TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. *Nature* 451, 725–729.

Ishii, K. J., Suzuki, K., Coban, C., Takeshita, F., Itoh, Y., Matoba, H., et al. (2001). Genomic DNA released by dying cells induces the maturation of APCs. *J. Immunol.* 167, 2602–2607.

Ishikawa, H., and Barber, G. N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 455, 674–678.

Ishikawa, H., Ma, Z., and Barber, G. N. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. *Nature* 461, 788–792.

Janicki, S. M., Tsukamoto, T., Salghetti, S. E., Tansey, W. P., Sachidanandam, R., Prasanth, K. V., et al. (2004). From silencing to gene expression: real-time analysis in single cells. *Cell* 116, 683–698.

Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., et al. (2005). IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. *Nat. Immunol.* 6, 981–988.

Kawane, K., Ohtani, M., Miwa, K., Kizawa, T., Kanbara, Y., Yoshioka, Y., et al. (2006). Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. *Nature* 443, 998–1002.

Kawasaki, H., Schiltz, L., Chiu, R., Itakura, K., Taira, K., Nakatani, Y., et al. (2000). ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. *Nature* 405, 195–200.

Kawashima, A., Tanigawa, K., Akama, T., Wu, H., Sue, M., Yoshihara, A., et al. (2011a). Fragments of genomic DNA released by injured cells activate innate immunity and suppress endocrine function in the thyroid. *Endocrinology* 152, 1702–1712.

Kawashima, A., Tanigawa, K., Akama, T., Yoshihara, A., Ishii, N., and Suzuki, K. (2011b). Innate immune activation and thyroid autoimmunity. *J. Clin. Endocrinol. Metab.* 96, 3661–3671.

Kim, T., Pazhoor, S., Bao, M., Zhang, Z., Hanabuchi, S., Facchinetti, V., et al. (2010). Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. *Proc. Natl. Acad. Sci. U.S.A.* 107, 15181–15186.

Kimura, H. (2005). Histone dynamics in living cells revealed by photobleaching. *DNA Repair (Amst.)* 4, 939–950.

Kobiyama, K., Takeshita, F., Jounai, N., Sakaue-Sawano, A., Miyawaki, A., Ishii, K. J., et al. (2010). Extrachromosomal histone H2B mediates innate antiviral immune responses induced by intracellular double-stranded DNA. *J. Virol.* 84, 822–832.

Konishi, A., Shimizu, S., Hirota, J., Takao, T., Fan, Y., Matsuoka, Y., et al. (2003). Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks. *Cell* 114, 673–688.

Koshland, D., and Strunnikov, A. (1996). Mitotic chromosome condensation. *Annu. Rev. Cell Dev. Biol.* 12, 305–333.

Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., et al. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374, 546–549.

Kumar, H., Kawai, T., Kato, H., Sato, S., Takahashi, K., Coban, C., et al. (2006). Essential role of IPS-1 in innate immune responses against RNA viruses. *J. Exp. Med.* 203, 1795–1803.

Lee-Kirsch, M. A., Chowdhury, D., Harvey, S., Gong, M., Senenko, L., Engel, K., et al. (2007a). A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. *J. Mol. Med.* 85, 531–537.

Lee-Kirsch, M. A., Gong, M., Chowdhury, D., Senenko, L., Engel, K., Lee, Y. A., et al. (2007b). Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. *Nat. Genet.* 39, 1065–1067.

Liang, Y., Quenelle, D., Vogel, J. L., Mascaro, C., Ortega, A., and Kristie, T. M. (2013). A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. *MBio* 4, e00558–e00612.

Liang, Y., Vogel, J. L., Narayanan, A., Peng, H., and Kristie, T. M. (2009). Inhibition of the histone demethylase LSD1 blocks alpha-herpesvirus lytic replication and reactivation from latency. Nat. Med. 15, 1312–1317.

Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251–260.

Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschlager, R., et al. (2005). Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167–1172.

Morita, M., Stamp, G., Robins, P., Dulic, A., Rosewell, I., Hrivnak, G., et al. (2004). Gene-targeted mice lacking the Trex1 (DNase III) 3′–>5′ DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol. 24, 6719–6727.

Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, H. G., and Moroy, T. (2000). Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25, 177–181.

Nathan, D., Ingvarsdottir, K., Sterner, D. E., Bylebyl, G. R., Dokmanovic, M., Dorsey, J. A., et al. (2006). Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev. 20, 966–976.

Parvatiyar, K., Zhang, Z., Teles, R. M., Ouyang, S., Jiang, Y., Iyer, S. S., et al. (2012). The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13, 1155–1161.

Radic, M., Marion, T., and Monestier, M. (2004). Nucleosomes are exposed at the cell surface in apoptosis. J. Immunol. 172, 6692–6700.

Redon, C., Pilch, D., Rogakou, E., Sedelnikova, O., Newrock, K., and Bonner, W. (2002). Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 12, 162–169.

Richards, A., Van Den Maagdenberg, A. M., Jen, J. C., Kavanagh, D., Bertram, P., Spitzer, D., et al. (2007). C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause

autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat. Genet. 39, 1068–1070.

Roberts, T. L., Idris, A., Dunn, J. A., Kelly, G. M., Burnton, C. M., Hodgson, S., et al. (2009). HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323, 1057–1060.

Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y., and Bonner, W. M. (2000). Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275, 9390–9395.

Rotem, Z., Cox, R. A., and Isaacs, A. (1963). Inhibition of virus multiplication by foreign nucleic acid. Nature 197, 564–566.

Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002). Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195.

Schiltz, R. L., Mizzen, C. A., Vassilev, A., Cook, R. G., Allis, C. D., and Nakatani, Y. (1999). Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. J. Biol. Chem. 274, 1189–1192.

Seth, R. B., Sun, L., Ea, C. K., and Chen, Z. J. (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669–682.

Stacey, K. J., Ross, I. L., and Hume, D. A. (1993). Electroporation and DNA-dependent cell death in murine macrophages. Immunol. Cell Biol. 71(Pt 2), 75–85.

Stetson, D. B., and Medzhitov, R. (2006). Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24, 93–103.

Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z. J. (2013). Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791.

Suzuki, K., Mori, A., Ishii, K. J., Saito, J., Singer, D. S., Klinman, D. M., et al. (1999). Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl. Acad. Sci. U.S.A. 96, 2285–2290.

Takaoka, A., Wang, Z., Choi, M. K., Yanai, H., Negishi, H., Ban, T., et

al. (2007). DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501–505.

Tokunaga, T., Yamamoto, H., Shimada, S., Abe, H., Fukuda, T., Fujisawa, Y., et al. (1984). Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72, 955–962.

Unterholzner, L., Keating, S. E., Baran, M., Horan, K. A., Jensen, S. B., Sharma, S., et al. (2010). IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 997–1004.

Wang, Y., Chen, Y., Xin, L., Beverley, S. M., Carlsen, E. D., Popov, V., et al. (2011). Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes. Infect. Immun. 79, 1124–1133.

Wittemann, B., Neuer, G., Michels, H., Truckenbrodt, H., and Bautz, F. A. (1990). Autoantibodies to nonhistone chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis. Arthritis Rheum. 33, 1378–1383.

Wu, J., Huen, M. S., Lu, L. Y., Ye, L., Dou, Y., Ljungman, M., et al. (2009). Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol. Cell. Biol. 29, 849–860.

Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C. T., Semeraro, F., et al. (2009). Extracellular histones are major mediators of death in sepsis. Nat. Med. 15, 1318–1321.

Xu, L. G., Wang, Y. Y., Han, K. J., Li, L. Y., Zhai, Z., and Shu, H. B. (2005). VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19, 727–740.

Yanai, H., Ban, T., Wang, Z., Choi, M. K., Kawamura, T., Negishi, H., et al. (2009). HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462, 99–103.

Yang, P., An, H., Liu, X., Wen, M., Zheng, Y., Rui, Y., et al. (2010). The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat. Immunol. 11, 487–494.

Yasutomo, K., Horiuchi, T., Kagami, S., Tsukamoto, H., Hashimura, C., Urushihara, M., et al. (2001). Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28, 313–314.

Yoshida, H., Okabe, Y., Kawane, K., Fukuyama, H., and Nagata, S. (2005). Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 6, 49–56.

Zhang, X., Brann, T. W., Zhou, M., Yang, J., Oguariri, R. M., Lidie, K. B., et al. (2011a). Cutting edge: Ku70 is a novel cytosolic DNA sensor that induces type III rather than type I IFN. J. Immunol. 186, 4541–4545.

Zhang, Z., Yuan, B., Bao, M., Lu, N., Kim, T., and Liu, Y. J. (2011b). The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 12, 959–965.

Zhu, B., Zheng, Y., Pham, A. D., Mandal, S. S., Erdjument-Bromage, H., Tempst, P., et al. (2005). Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol. Cell 20, 601–611.

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant

Choon Kit Tang[1,2,3,4], Taiki Aoshi[4,5], Nao Jounai[5], Junichi Ito[6], Keiichi Ohata[2], Kouji Kobiyama[4,5], Benoit H. Dessailly[6], Etsushi Kuroda[4,5], Shizuo Akira[3], Kenji Mizuguchi[6], Cevayir Coban[2], Ken J. Ishii[4,5]*

1 Singapore Immunology Network, Agency for Science and Technology Research, Singapore, 2 Malaria Immunology Laboratory, Immunology Frontier Research Centre (IFReC), Osaka University, Japan, 3 Host Defense Laboratory, IFReC, Osaka University, Japan, 4 Vaccine Science Laboratory, IFReC, Osaka University, Japan, 5 Laboratory of Adjuvant Innovation, NIBIO, Osaka, Japan, 6 Laboratory of Bioinformatics, National Institute of Biomedical Innovation (NIBIO), Osaka, Japan

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant. In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine which led to significant increase in protective responses against live influenza virus challenge in mice compared to split vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway via IRF3 for potential applications including vaccines against influenza which requires a high safety profile.

Introduction

DMXAA was developed as a vascular disruptive agent for use in cancer therapy. Several clinical trials, including a recently completed phase III clinical trial for non-small cell lung carcinoma, have shown that DMXAA is safe and well-tolerated in humans [1]. It is a cell-permeable small molecule which reduces tumor load by inducing apoptosis in tumor vascular endothelium thereby reducing blood flow to solid tumor [2]. Further investigations into the properties of DMXAA have revealed that it is a strongly immunogenic molecule. The anti-neoplastic property of DMXAA is largely attributed to its induction of TNFα which can be detected in the serum and tumor micro-environment within hours of administration [3]. It can activate several inflammatory cell signaling pathways, including extracellular signal-regulated kinases 1 and 2, c-Jun N-terminal kinases, and cytosolic nucleotide-binding oligomerization domain 1 and 2-like receptors [4,5]. In addition, DMXAA is a strong inducer of reactive oxygen species (ROS) [6]. The most striking immunogenic feature of DMXAA is its induction of immediate and predominant type-I-IFN [7]. DMXAA resembles viral infections and double stranded DNA (dsDNA) in the inflammatory signaling events it triggers to induce type-I-IFN production [8]. It utilizes the TBK1-IRF3 signaling pathway without the involvement of Toll-like receptors (TLRs) or RNA helicases for its mechanism of type-I-IFN induction. For the cell signaling events that are upstream of TBK1 phosphorylation, DMXAA was shown to initiate the translocation of the E3 ubiquitin ligase tripartite motif 56 (TRIM56) from the cytoplasm into intracellular punctate structures where the Stimulator of Interferon Genes (STING) was simultaneously recruited [9]. STING is an adaptor molecule that is vital to the induction of type-I-IFN during viral infection [10] and stimulation with cytosolic dsDNA [11] and the bacterial second messenger product, cyclic diguanylate (c-di-GMP) [12]. DMXAA was recently demonstrated to require STING for the production of IFN-β [13]. Due to its ability to induce strong type-I-IFN, DMXAA was found to be an effective antiviral agent against influenza [14,15].

In addition to the induction of pro-inflammatory cytokines, DMXAA can induce the direct activation of antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs). In-vivo administration of DMXAA induced maturation of DCs in draining lymph node of tumor bearing mice within 24 h. This was shortly followed by the increase of tumor antigen specific CD8 T cells and their migration to tumor sites due to chemokines such as CCL2 and CXCL10 that were released by the activated APCs [16]. Based on these immunogenic properties of DMXAA, we hypothesize that DMXAA could function as an adjuvant. In this report, we demonstrate in mouse models that DMXAA could indeed promote the adaptive immune response in immunization studies against influenza virus and be a potential adjuvant candidate.

Materials and Methods

Mice and immunizations

Ifnar[-/-] and *Irf3*[-/-] mice were of C57BL/6 background and *IL-33*[-/-] mice were of BALB/c background. The development of these animals was described elsewhere [17–19]. Wild-type (WT) controls were purchased from CLEA, Japan. All animal experiments were conducted in accordance with the guidelines of the Animal Care and Use Committee of Research Institute for Microbial Diseases and Immunology Frontier Research Center of Osaka University, who specifically approved this study. All animal experiments were performed to ameliorate suffering according to the guideline of ASUDC of RIMD and IFREC of Osaka university. Endotoxin-free chicken egg Ovalbumin (OVA) (Seikagaku Biobusiness) was mixed with various adjuvants, including DMXAA (Sigma-Aldrich), aluminum hydroxide suspension (Sigma Aldrich) and K-type CpG ODN 2006 (InvivoGen), in PBS prior to immunization. DMXAA was dissolved in 5% NaHCO$_3$ and was ensured endotoxin-free by analysis with LAL testing (Lonza). In all immunization experiments, mice were injected intradermally at the base of tail on days 0 and 14 and were bled on day 21.

Generation and *in-vitro* stimulation of bone marrow derived dendritic cells

In-vitro grown DCs were prepared by incubating red blood cells-lysed bone marrow cells from WT and various knockout mice with 20 ng/ml of GM-CSF (Peprotech, NJ, USA) for 5 days as previously described in [20]. On day 5, DCs were stimulated with DMXAA, lipopolysaccharides (LPS) (Sigma Aldrich, MO, USA), and Lipofectamine 2000 (Invitrogen, NY, USA) complexed c-di-GMP (Biolog, Bremen, Germany) for 6 h before the supernatant were collected and cytokines measured. The level of DC maturation induced by the various stimuli were determined by using flow cytometry to detect CD86 expression on CD11c$^+$ cells and presented as histogram plots.

Cytokine ELISA

TNFα was measured using the R&D DuoSet® ELISA Development Systems (R&D Systems). IFNβ was measured by ELISA, using rat monoclonal [7F–D3] antibody to Interferon beta (ab24324, Abcam) and rabbit polyclonal antibody to Interferon β (#AB2215, Millipore) and finally with sheep antibody to rabbit IgG (H&L-HRP; ab97095, Abcam). Standard curves were generated using recombinant mouse IFNβ (12400-1, Interferon Source PBL). Results reported in the figures are averages of three samples with errors displayed as standard deviations. Antibody responses to OVA and SV were determined by ELISA where plates were coated with OVA protein and SV respectively. The OVA and SV specific antibodies were detected using goat anti-mouse IgG, IgG1, IgG2a or IgG2c-HRP (Southern Biotech). The relative antibody titers were determined directly from the standard curve generated from positive serum by solving the regression line equation. All ELISAs were developed with the KPL TMB Microwell Peroxidase Substrate System (KPL).

Influenza virus infection and vaccination

Mice were immunized intradermally, at the base of the tail, on days 0 and 14, with 100 µg DMXAA and 0.75 µg of New Caledonia/20/1999 (H1N1), prepared as described [21]. On day 21, the immunized mice were anesthetized with ketamine before they were intranasally infected with 1×10^5 pfu of A/Puerto Rico/8/34 (PR) (H1N1) virus. All efforts were made to reduce suffering to the animal. Challenged mice were monitored daily for their body weight loss and any signs of sickness. Mice that were in a moribund condition or had loss more than 25% of body weight were considered to have reached an experimental endpoint and were humanely euthanized by cervical dislocation.

Statistical analysis

All data were reported as means ± standard deviation. Students t-test was used to compare significant differences between two groups, whereas one-way analysis of variance with Bonferroni's post-test was used to compare differences among three or more groups. Log-rank (Mantel-Cox) tests was used to analyze significant difference between survival curves.

Results

DMXAA has adjuvant properties and induces preferential type-2 response

To determine if the immunogenic property of DMXAA could adjuvant vaccines, we utilized the OVA model antigen system where C57BL/6 mice were immunized with OVA mixed with DMXAA. We found that DMXAA could significantly augment specific immune responses against OVA, as indicated by the increase in serum anti-OVA total IgG (tIgG) titers compared to OVA alone immunized group (Figure 1A). The adjuvant effect was dependent on the dose of DMXAA. In addition, it was observed to have noticeable but insignificant adjuvant effect at a low dose of 10 µg. The immune response induced by the combination of DMXAA and OVA was long-lasting and could be detected as late as 150 days after the final immunization (Figure 1B). To evaluate its efficacy, we compared DMXAA with the established adjuvants, Alum and CpG DNA, which induce predominantly T$_H$2 and T$_H$1 immune responses, respectively. Mice immunized with OVA plus DMXAA (100 µg) generated comparable anti-OVA tIgG titers as Alum (665 µg) and CpG DNA (25 µg) adjuvanted groups (Figure 1C). DMXAA resembled Alum in generating predominantly T$_H$2 type responses as indicated by the induction of higher IgG1 than IgG2c titers (Figure 1D and 1E). In contrast, CpG DNA induced higher IgG2c and lower IgG1 levels. We have also analyzed OVA specific T cell responses by stimulating splenocytes of immunized mice with whole OVA protein or its CD4 and CD8 epitopes followed by measuring IFN-γ secretion. No T-cell responses could be detected in OVA plus Alum or DMXAA groups, whereas splenocytes from the OVA plus CpG group responded with high IFN-γ secretion in the presence CD8 peptide and whole OVA protein (Figure 1F). *In-vivo* depletion of CD4 T cells prior to immunization with OVA and DMXAA completely abrogated the production of OVA-specific antibodies (Figure 1G), suggesting that the generation of adaptive immune responses by DMXAA was CD4 T cell-dependent. These results indicate that DMXAA possesses immuno-stimulatory properties that can function effectively as an adjuvant for vaccines.

Adjuvant effect of DMXAA is dependent on the type-I-IFN response induced by IRF3 signaling

DMXAA has been shown to activate the TBK1-IRF-3 signaling pathway to induce strong IFNβ response from mouse embryonic fibroblasts (MEFs), macrophages and dendritic cells [7]. A recent study also reported that DMXAA could induce IL-33 up-regulation through IRF3 dependent mechanism [22]. IL-33 promotes humoral immunity by triggering the release of T$_H$2 cytokines such as IL-4, IL-5 and IL-13 from polarised naive T cells [23]. Therefore we would like to determine if the adjuvant effect of DMXAA requires IRF3-dependent type-I-IFN secretion and

– 210 –

Figure 1. DMXAA acts as a potent adjuvant. (A) Anti-OVA tIgG titers of C57BL/6 mice immunized with 100 µg OVA plus the indicated doses of DMXAA (µg). (B) Anti-OVA tIgG titers of C57BL/6 mice 21 days and 150 days after immunization with 100 µg OVA and 100 µg DMXAA. (C–E) C57BL/6 mice were immunized twice i.d. with 100 µg OVA plus DMXAA (100 µg), Alum (665 µg) or CpG DNA (25 µg) and the induction of (C) tIgG, (D) IgG1 and (E) IgG2c antibody responses against OVA were assessed. (F) IFN-γ secretion from splenocytes of immunized mice that were stimulated for 48 h with CD4 and CD8 OVA peptides and whole OVA protein. (G) Anti-OVA tIgG titers of C57BL/6 mice injected i.v. with 200 µg anti-CD4 (GK1.5) antibodies prior to immunization with 100 µg OVA and 100 µg DMXAA. Results presented are representatives of three separate experiments. *<0.05, ** $P<0.01$, *** $P<0.001$ by Students t-test when comparing between two groups and one-way ANOVA with Bonferroni's post-test when comparing three or more groups.
doi:10.1371/journal.pone.0060038.g001

could the induction of preferential T_H2 type response be due to its up-regulation of IL-33.

To address this, OVA immunization studies were performed on mice lacking IRF3 ($Irf3^{-/-}$), IFNαβ receptor ($Ifnar^{-/-}$) and IL-33 ($Il-33^{-/-}$). As observed in Figure 2A, the anti-OVA tIgG (Figure 2A) titers from $Irf3^{-/-}$ and $Ifnar^{-/-}$ mice were significantly inhibited compared to WT C57BL/6 mice. This indicates that the adjuvant effect of DMXAA was strongly dependent on IRF3 mediated transcription and responses mediated by type-I-IFN. In contrast to $Irf3^{-/-}$ and $Ifnar^{-/-}$ mice, $Il-33^{-/-}$ mice showed comparable levels of tIgG antibody response as WT BALB/c immunized mice (Figure 2B). Moreover, the preference for the induction of IgG1 (Figure 2C) over IgG2a (Figure 2D) subtype as observed in WT BALB/c mice remained the same in $Il-33^{-/-}$ mice. To further support the dependence on IRF3 mediated type-I-IFN for DMXAA adjuvant effect, bone marrow derived DCs from $Irf3^{-/-}$, $Ifnar^{-/-}$ and WT mice were stimulated with DMXAA (Figure 2E–G). Cyclic diguanylate (c-di-GMP) is an IRF3-dependent type-I-IFN inducer and was included as a control. As observed in figure 2E, $Irf3^{-/-}$ DCs were unable to induce IFNβ response whilst $Ifnar^{-/-}$ DC responded with levels comparable to WT DCs. Therefore indicating that the lack of DMXAA adjuvant effect observed in $Ifnar^{-/-}$ mice was not due to the inability to induce type-I-IFN but rather it was the inability to respond to it.

Although $Irf3^{-/-}$ and $Ifnar^{-/-}$ mice did not respond to the adjuvant effect of DMXAA, it was found to be capable of inducing IL-6 (Figure 2F) and TNFα (Figure 2G) response from $Irf3^{-/-}$ and $Ifnar^{-/-}$ DCs. In addition, the DC maturation effect of DMXAA was still present in $Irf3^{-/-}$ and $Ifnar^{-/-}$ DCs in the same order of magnitude as WT DCs (Figure 2H). These data suggest that other stimulatory pathways of DMXAA remained intact in $Irf3^{-/-}$ mice but they did not play a role in the adjuvant effects of DMXAA. Collectively, we demonstrate that the adjuvant effect of DMXAA is directly dependent on IRF3 mediated type-I-IFN induction and that the reported IL-33 up-regulation by DMXAA is not involved in raising immunogenicity of the vaccine or the skewing towards Th2 type response.

DMXAA is a potent adjuvant for influenza split virus vaccine and enhances protection against influenza challenge

In our previous report, we have demonstrated that in contrast to influenza whole virus vaccine (WV), split vaccine (SV) was unable to induce type-I-IFN production from plasmacytoid DCs [21]. This was due to the lack of RNA content in the SV preparation required to trigger TLR7 activation. As a result, SV immunizations were less protective against lethal influenza challenge as compared to WV immunizations. Hence, we would like to

Figure 2. Adjuvant effects of DMXAA require type-I-IFN responses induced by IRF3 activation. Anti-OVA (A) tIgG antibody responses of WT C57BL/6, Ifnar[-/-] and Irf3[-/-] mice immunized twice i.d. with 10 µg OVA plus 100 µg DMXAA. (B) tIgG, (C) IgG1 and (D) IgG2a antibody titers against OVA in WT BALB/c and Il-33[-/-] mice immunized twice i.d. with 10 µg OVA plus 100 µg DMXAA. Results presented are pooled titers from two separate experiments. In-vitro cultured DCs derived from WT, Ifnar[-/-] and Irf3[-/-] mice were stimulated with DMXAA (2.5 µg/ml), LPS (1 µg/ml) or lipofectamine complexed c-di-GMP (10 µg/ml) for 6 h before the supernatant were collected and analysed for (E) IFNβ, (F) IL-6 and (G) TNFα secretion and CD11c[+] cells were analysed for CD86 expression (H). Results presented are average of triplicate conditions ± SD and are representative of three separate experiments. *** P<0.001 one-way ANOVA with Bonferroni's post-test.
doi:10.1371/journal.pone.0060038.g002

determine if the type-I-IFN dependent adjuvant effect of DMXAA could adjuvant SV and immunized mice from live flu challenges. C57BL/6 WT mice were immunized intradermally with SV prepared from New Caledonia/20/1999 (H1N1) and mixed with

DMXAA. We found that SV plus DMXAA induced higher tIgG antibody responses than SV alone immunizations (Figure 3A). Similar to OVA immunization studies, the adjuvant effect of DMXAA induced higher IgG1 than IgG2c titers to SV (Figure 3B

and 3C). Next, we challenged the immunized mice with a high dose of A/Puerto Rico/8/34 (PR) (H1N1). As seen in Figure 3D, naive mice were quick to succumb to the selected dose of live influenza challenge whilst SV alone immunized mice were offered low level protection (Figure 3A). Although SV alone immunizations had low antibody titers, it was found to be mildly immunogenic and capable of inducing detectable CXCL10 and Anti-HA BALF IgA production [21] that may account for the low level of protective response observed. In contrast, mice immunized with SV plus DMXAA had significantly higher survival rates than naive mice and mice immunized with SV alone (Figure 3D). 11 out of 12 mice that were immunized with SV + DMXAA survived the lethal challenge compared to the 3 out of 12 SV alone group. It was also observable from the rate of weight-loss that SV plus DMXAA immunized mice had a lesser degree of disease-induced morbidity and were able to recover from the infection at a faster rate than control groups (Figure 3E). To exclude the possible role of DMXAA-induced innate immune responses in the protection against lethal challenge, the survival rate of mice injected with DMXAA alone without SV was determined and found to be similar as naïve mice (Figure 3D). Therefore the protective response observed in SV + DMXAA immunized group was due to the adaptive response generated from the immunization and not the innate immune response triggered by DMXAA. These results demonstrate that DMXAA is an efficacious adjuvant for SV vaccine.

Discussion

A large cohort Phase III clinical trial of DMXAA on patients with non-small cell lung carcinoma was recently halted due to inefficacy although it was shown to be well tolerated [1]. As opposed to an earlier successful Phase II clinical trial [24], the Phase III trial showed no overall survival between DMXAA and placebo treated groups. The researchers conducting the clinical trial reasoned that a smaller sample size in the phase II trial overestimated the efficacy of DMXAA. The future of DMXAA as a vascular disruptive agent for cancer therapy is therefore uncertain. In this report, we have demonstrated that the immunogenic properties of DMXAA could be harnessed to adjuvant vaccines with its acceptable safety profile. A local low-dose of DMXAA was capable of adjuvanting vaccines with efficacy that was comparable to the well-studied adjuvants, Alum and CpG. The adjuvant activity was observed using amounts as low as 10 μg per mouse, which was a smaller dose than the 30 mg/kg required for the vascular disruptive effect [25]. When extrapolated to human use, the lower dose required for the adjuvant activity serves to promote DMXAA as a candidate for vaccine adjuvant.

Despite the activation of several distinct inflammatory signaling pathways, we narrowed the immune activity responsible for the adjuvant effect of DMXAA to the IRF3 mediated activation of type-I-IFN. This is surprising as DMXAA induced biased T_H2 response while type-I-IFN is commonly associated with the


Figure 3. Adjuvant effect of DMXAA can improve potency of influenza SV vaccine and protect mice from a lethal challenge. C57BL/6 mice were immunized twice i.d. with 0.75 μg SV and 100 μg DMXAA, and their sera were assessed for anti-SV (A) tIgG, (B) IgG1 and (C) IgG2c antibodies. ** $P<0.01$ by Students t-test. Results presented are pooled from two separate experiments. (D) C57BL/6 mice that had received two i.d. injections of PBS (open square), 100 μg DMXAA alone (open circle), 0.75 μg SV alone (grey-filled circle) or SV plus DMXAA (black filled circle) were challenged with a lethal dose of A/Puerto Rico/8/34 (PR) (H1N1) 7 days after the final immunization (n = 6 mice per experimental group). Results presented are pooled from two separate experiments. Survival rates were recorded daily and statistical analyses were performed using the log-rank (Mantel-Cox) test where ** and *** denotes $p<0.01$ and $p<0.001$ respectively (E) The rate of weight-loss by the challenged mice were monitored and presented as an average percentage of the initial base weight ± standard error. * denotes $p<0.05$ vs SV alone by Student's T-test.
doi:10.1371/journal.pone.0060038.g003

– 213 –

generation of T$_H$1 response *in-vivo* [26]. The recent study reporting that DMXAA could induce IL-33 up-regulation through IRF3 dependent mechanism made us question if this could be the reason for the unusual observation [22]. However, immunization studies performed on *Il-33$^{-/-}$* mice confirmed that IL-33 was not involved in the adjuvant effect of DMXAA or its skewing towards T$_H$2 response. We have recently reported that Alum mediates enhancement of T$_H$2 response through the DNA sensing pathway triggered by the release of dsDNA from dying host cells [18]. However, we found that DMXAA did not induce significant increase in free dsDNA in the peritoneal lavage of mice when injected intraperitoneally as opposed to Alum (data not shown). Therefore the mechanism through which DMXAA induced preferential T$_H$2 type responses remains elusive and requires further investigation. It is possible that the production of IL-6 by DMXAA to be involved as it has been known to inhibit T$_H$1 polarization by activating NFAT, c-maf and SOCS-1 [27,28] and induce the humoral immunity promoting cytokine, IL-21.

The revealing of DMXAA adjuvant property suggests that it could adjuvant tumor associated antigens and activate the adaptive immune system against cancer cells as part of its anti-tumor response. So far, there are no reports on DMXAA raising humoral immunity against tumor cells with its T$_H$2 enhancing capability. However, there is evidence which suggests that DMXAA could act as a cancer vaccine adjuvant. For example,

it was demonstrated that the administration of DMXAA in tumor bearing mice could increase the number of circulating specific CD8 T-cells [16]. It was also shown to have a positive influence in a separate study which investigated if the anti-cancer property of systemic high-dose DMXAA could work in combination with the adaptive immune response generated by DNA vaccine to protect mice against tumor challenges [29].

In summary, results from this report have shown that DMXAA is capable of functioning as an adjuvant with a defined mechanism that acts specifically on the IRF3 dependent induction of type-I-IFN. DMXAA has already been investigated for applications in antiviral [15] and anti-bacterial [30] therapies and here we demonstrate that it is capable of adjuvanting vaccines as well.

Acknowledgments

Author Contributions

Conceived and designed the experiments: CKT CC KJI. Performed the experiments: CKT JI NJ. Analyzed the data: CKT CC KJI. Contributed reagents/materials/analysis tools: TA KO KK BHD EK KM SA. Wrote the paper: CKT CC KJI.

References

1. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, et al. (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29: 2965–2971.
2. Ching LM, Zwain S, Baguley BC (2004) Relationship between tumor endothelial cell apoptosis and tumor blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90: 906–910.
3. Zhao L, Ching LM, Kestell P, Kelland LR, Baguley BC (2005) Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116: 322–326.
4. Sun J, Wang LC, Fridlender ZG, Kapoor V, Cheng G, et al. (2011) Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. Biochem Pharmacol 82: 1175–1185.
5. Cheng G, Sun J, Fridlender ZG, Wang LC, Ching LM, et al. (2010) Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5′6-dimethylxanthenone-4-acetic acid (Vadimezan). J Biol Chem 285: 10553–10562.
6. Brauer R, Wang LC, Woon ST, Bridewell DJ, Henare K, et al. (2010) Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia 12: 755–765.
7. Roberts ZJ, Goutagny N, Perera PY, Kato H, Kumar H, et al. (2007) The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204: 1559–1569.
8. Desmet CJ, Ishii KJ (2012) Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 12: 479–491.
9. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, et al. (2010) The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 33: 765–776.
10. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455: 674–678.
11. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461: 788–792.
12. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, et al. (2011) STING is a direct innate immune sensor of cyclic di-GMP. Nature 478: 515–518.
13. Prantner D, Perkins DJ, Lai W, Williams MS, Sharma S, et al. (2012) 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates Stimulator of Interferon Gene (STING)- dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem.
14. Cheng G, Wang LC, Fridlender ZG, Cheng GS, Chen B, et al. (2011) Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol 45: 480–488.
15. Shirey KA, Nhu QM, Yim KC, Roberts ZJ, Teijaro JR, et al. (2011) The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol 89: 351–357.
16. Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, et al. (2007) The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 67: 7011–7019.
17. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, et al. (2006) A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 7: 40–48.
18. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, et al. (2011) DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 17: 996–1002.
19. Coban C, Igari Y, Yagi M, Reimer T, Koyama S, et al. (2010) Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 7: 50–61.
20. Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, et al. (2009) Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials 30: 1389–1400.
21. Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, et al. (2010) Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2: 25ra24.
22. Polumuri SK, Jayakar GG, Shirey KA, Roberts ZJ, Perkins DJ, et al. (2012) Transcriptional Regulation of Murine IL-33 by TLR and Non-TLR Agonists. J Immunol.
23. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490.
24. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, et al. (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99: 2006–2012.
25. Laws AL, Matthew AM, Double JA, Bibby MC (1995) Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 71: 1204–1209.
26. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, et al. (2002) Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169: 375–383.
27. Yang Y, Ochando J, Yopp A, Bromberg JS, Ding Y (2005) IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol 174: 2720–2729.
28. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39: 531–536.
29. Peng S, Monie A, Pang X, Hung CF, Wu TC (2011) Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci 18: 21.
30. Cole LE, Santiago A, Barry E, Kang TJ, Shirey KA, et al. (2008) Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol 180: 6885–6891.

License to Publish

LANDES
BIOSCIENCE

Journal Title: _Human Vaccines & Immunotherapeutics_ Author(s): _Cohen C, Kobiyama K,_

Manuscript #: _2012 HV 0435_ _Jonai N, Tsukai M and Ishii KJ_

Title of the Contribution: _DNA Vaccines : A simple DNA sensing matter?_

To: Landes Bioscience (hereinafter "Landes")

1. In consideration of Landes agreeing to publish the Contribution, the Authors grant to Landes an exclusive license to:
   (a) Publish, reproduce, transmit, distribute and display the Contribution in all forms and formats whether now known or hereafter conceived or developed throughout the world,
   (b) Prepare translations and other derivative works based on the Contribution,
   (c) License any or all of the foregoing to others.

2. Copyright. Ownership of the copyright remains with the Authors, and provided that, when reproducing all or part of the Contribution, the Authors first acknowledge and reference publication in the Journal, the Authors retain the following non-exclusive rights:
   (a) Use of all or part of the Contribution (after publication in the Journal) in any book, article, thesis or dissertation written by the Authors without first requiring permission from Landes.
   (b) To reuse figures or tables created by the Authors and contained in the Contribution in the Authors' future works.
   (c) Make photocopies of all or part of the Contribution for use by the Authors and any academic institution where they work for the purpose of classroom teaching.
   (d) To post a copy of the Contribution as accepted for publication after peer review on the Author's personal website or institutional repository, or the Author's funding body's designated archive as soon as possible but no later than 12 months after publication by the Journal.

3. Author's Duties:
   (a) If the Contribution contains copyrighted material not owned by the Authors, then Authors shall obtain written permission from the copyright owner, in a form acceptable to Landes, to include such copyrighted material in the Contribution and to reprint it in the Journal, and shall deliver such written permission to Landes together with delivery of the manuscript of the Contribution.
   (b) Landes may copyedit the Contribution as necessary in order to prepare it for publication in the Journal. The Author will proofread and correct the edited manuscript and shall return the proofs in a timely manner as directed. If proofs are not corrected in a timely manner, Landes may proceed with the publication of the Contribution as it deems appropriate.
   (c) The full text of the Contribution may not be posted on any social network, commercial website or self-archived on any website that is not the Author's personal website or the funding

body's database prior to publication and for the first 12 months after publication unless the Open Access fee has been paid to Landes.
   (d) This license must be signed by the Authors and delivered to Landes as a condition for publication of the Contribution in the Journal.

4. The Authors warrant and represent that:
   (a) The Contribution has not been previously published, is not in the public domain and is the original work of the Authors.
   (b) The Authors are the sole owners of the copyright of the Contribution and have the full power and authority to assign the license to Landes. If the Contribution includes materials of others, the Authors have obtained permission of the original copyright owner to enable them to grant the rights contained herein.
   (c) The Contribution does not infringe the copyright or any other proprietary right of any party.
   (d) The Contribution contains no material that is defamatory, violates any right of privacy or is otherwise contrary to law.
   (e) All statements in the Contribution asserted as facts are based upon reasonable research for accuracy.
   (f) No formula or procedure contained in the Contribution would cause injury if used in accordance with the instructions and/or warnings contained in the Contribution.

5. Authors employed by the US Government:
   If the Author's contribution was performed as part of the Author's official duties as an employee of the US Government, the Publisher acknowledges that copyright may not be established in the United States.

6. Authors with funding from agencies with deposition requirements:
   (a) For Authors who must comply with NIH Public Access Policy, Landes will deposit an electronic version of the final, peer-reviewed manuscript upon acceptance for publication in NIH's PubMed Central archive to be publicly available no later than 12 months after publication by the Journal.
   (b) For Authors who must comply with UKPMC funding agencies (including Wellcome Trust) Landes will desposit an electronic version of the final, peer-reviewed manuscript upon acceptance for publication in the UKPMC archive to be available no later than 6 months after publication by the Journal.
   (c) For Authors who have paid the Open Access fee, please see the Open Access License Agreement.

Signed for and on behalf of the Authors: _[signature]_ Date: _Dec 15/2013_

Please print name: _Ken J. Ishii_

Microbe-dependent CD11b+ IgA+ plasma cells mediate robust early-phase intestinal IgA responses in mice

Jun Kunisawa[1,2,3,4,5], Masashi Gohda[1,2], Eri Hashimoto[1], Izumi Ishikawa[1], Morio Higuchi[1,6], Yuji Suzuki[1], Yoshiyuki Goto[1,5,7], Casandra Panea[7], Ivaylo I. Ivanov[7], Risa Sumiya[1], Lamichhane Aayam[1,2], Taichi Wake[1,6], So Tajiri[1,2], Yosuke Kurashima[1,5,6], Shiori Shikata[1], Shizuo Akira[8], Kiyoshi Takeda[5,9] & Hiroshi Kiyono[1,2,3,5,6]

Intestinal plasma cells predominantly produce immunoglobulin (Ig) A, however, their functional diversity remains poorly characterized. Here we show that murine intestinal IgA plasma cells can be newly classified into two populations on the basis of CD11b expression, which cannot be discriminated by currently known criteria such as general plasma cell markers, B cell origin and T cell dependence. CD11b+ IgA+ plasma cells require the lymphoid structure of Peyer's patches, produce more IgA than CD11b- IgA+ plasma cells, proliferate vigorously, and require microbial stimulation and IL-10 for their development and maintenance. These features allow CD11b+ IgA+ plasma cells to mediate early-phase antigen-specific intestinal IgA responses induced by oral immunization with protein antigen. These findings reveal the functional diversity of IgA+ plasma cells in the murine intestine.

[1] Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. [2] Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Chiba 277-8562, Japan. [3] International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. [4] Laboratory of Vaccine Materials, National Institute of Biomedical Innovation, Osaka 567-0085, Japan. [5] Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Tokyo 102-0075, Japan. [6] Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan. [7] Department of Microbiology and Immunology, Columbia University Medical Center, New York, New York 10032, USA. [8] Laboratory of Host Defense, WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan. [9] Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan. Correspondence and requests for materials should be addressed to J.K. (email: kunisawa@nibio.go.jp).

mmunoglobulin (Ig) A is an antibody found predominantly in the intestinal lumen, where it protects the host against pathogenic infections[1,2]. It also has an important role in the creation and maintenance of immunological homoeostasis by shaping homeostatic communities of commensal bacteria[3-5]. Indeed, some patients with IgA deficiency show marked susceptibility to infections with pathogens such as *Giardia lamblia*, *Campylobacter*, *Clostridium*, *Salmonella* and rotavirus; they also have increased incidences of intestinal immune diseases such as coeliac disease and inflammatory bowel diseases[6].

Peyer's patches (PPs) are the major sites for the initiation of antigen-specific intestinal IgA production, mainly in a T cell-dependent manner[7]. Intestinal IgA also originates from B1 cells. B1 cells differ from B2 cells in terms of origin, surface markers (for examples, B220, IgM, IgD, CD5, CD11b and CD23), growth properties and V_H repertoire[8-10]. B1 cells are predominantly present in the peritoneal cavity (PerC) and traffic into the intestinal compartment for the production of IgA against T cell-independent antigens such as DNA and phosphatidylcholine[11]. T cell independent antigen-specific IgA responses are also initiated in the isolated lymphoid follicles (ILFs), which are small clusters of B2 cells in the intestine[12].

Upon Ig class switching from μ to α, IgA+ B cells acquire the expression of type 1 sphingosine-1-phosphate receptor, CCR9 and α4β7 integrin, allowing them to migrate out from the PPs or PerC and traffic to the intestinal lamina propria (iLP)[11,13,14]. In the iLP, they further differentiate into IgA-secreting plasma cells (PCs) under the influence of terminal differentiation factors (for example, IL-6)[15]. As these locally produced IgA antibodies are continuously transported and secreted by epithelial cells as a form of secretory IgA into the intestinal lumen, stably high levels of IgA production are required for the maintenance of sufficient amounts of IgA; this production is determined by the generation, survival and function of IgA PCs.

Several lines of evidence have demonstrated that the function and survival of PCs in the systemic compartments (for example, spleen and bone marrow (BM)) are not only determined by intrinsic factors but are regulated by the presence of environmental niches[16]. As with systemic PCs, differentiation of IgA PCs in the iLP is regulated by exogenous factors such as IgA-enhancing cytokines (for example, interleukin (IL)-5, IL-6,

IL-10, IL-15, a proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF))[7,15]. In addition, microbial stimulation is required for the full effects of intestinal IgA. Indeed, germ-free (GF) mice have decreased intestinal IgA responses with immature structures of PPs and ILFs[17,18]. Previous studies in mono-associated GF mice have indicated that only a small proportion of the total amount of intestinal IgA is reactive to monoassociated bacteria; microbe-dependent IgA production is therefore mediated by polyclonal stimulation through innate immune receptors such as toll-like receptors, rather than through B cell receptors specific for microbial antigens[19,20]. Accumulating evidence has revealed the molecular and cellular pathways of IgA production mediated by innate immunity, including the involvement of myeloid differentiation primary response gene 88 (MyD88) in the regulation of tumour necrosis factor/inducible nitric oxide synthase-producing DCs in the iLP[21] and follicular DCs in the PPs[22]. However, the effects of microbial stimulation on the regulation of differentiated IgA+ PCs remain to be investigated. Here, we identified unique microbe-dependent subsets of IgA+ PCs, which add a new level of complexity to the intestinal IgA system of mice.

Results

Microbe dependency of intestinal IgA+ cells. To examine the immunological elements of intestinal IgA production associated with commensal bacteria, we initially compared the IgA+ cells of specific pathogen-free (SPF) and GF mice. Flow cytometric analysis showed that CD11b+ IgA+ cells accounted for about 30% of IgA+ cells, and we found a lack of CD11b+ IgA+ cells in the iLP of GF mice (Fig. 1a). Similarly, the numbers of intestinal CD11b+ IgA+ cells were reduced in both antibiotic-treated SPF mice and MyD88 KO mice (Fig. 1b–d). Immuno-histological analysis indicated that CD11b+ IgA+ cells were dispersed throughout the iLP of wild-type (WT) mice (Fig. 1d), although their frequency appeared lower than expected from the flow cytometric data, probably because of difference in methodological sensitivity. These findings collectively suggest that CD11b+ IgA+ cells are unique subset that requires MyD88-dependent microbial stimulation for its development and maintenance.


Figure 1 | Intestinal CD11b+ IgA+ cells require microbial stimulation. (a-c) Mononuclear cells were isolated from the small intestines of SPF or GF mice (a), mock- or antibiotic-treated SPF mice (b), or MyD88 WT or knockout (KO) mice (c) for analysis of IgA and CD11b expression by flow cytometry. Graphs show data from individual mice, and bars indicate median. Statistical analyses were performed with Mann-Whitney's U-test. (d) Specimens of small intestinal tissues of WT and MyD88 KO mice were stained for IgA and CD11b, and counterstained with 4′,6-diamidino-2-phenylindole. Data are representative of three independent experiments. Scale bars, 50 μm.

Intestinal CD11b$^+$ IgA$^+$ cells are PCs. We next aimed to characterize the CD11b$^+$ and CD11b$^-$ IgA$^+$ cells in the iLP. In addition to a gating strategy to exclude the possibility that the CD11b$^+$ IgA$^+$ cells detected by flow cytometry were doublets (Supplementary Fig. S1), we further performed a cytospin analysis and confirmed that both CD11b$^+$ and CD11b$^-$ IgA$^+$ cells had homogeneous morphology that was the same as that of PCs (for example, large irregular nuclei with prominent nucleoli), whereas CD11b^{hi} IgA$^-$ cells were composed of different kinds of cells, including eosinophils and macrophages (Fig. 2a). We also confirmed that both CD11b$^+$ and CD11b$^-$ IgA$^+$ cells did not express markers for macrophages (F4/80), DCs (CD11c) or eosinophils (CCR3) (Fig. 2b). Thus, CD11b$^+$ IgA$^+$ cells are neither doublets nor myeloid cells decorated by bound IgA on their surfaces.

CD11b$^+$ and CD11b$^-$ IgA$^+$ cells were identical in cell size and density, as determined by forward scatter (FSC) and side scatter (SSC), respectively, and by their surface expression patterns (CD19^{int}, B220$^-$, CD138$^+$, CD38^{hi} and CD40^{int}) (Fig. 2c). Although PCs in the systemic compartments (for example, the spleen) generally express little or no surface immunogloblin[23], we previously confirmed that CD38$^+$ CD138$^+$ cells in the iLP express IgA both on the cell surface and in the intracellular compartment (Supplementary Fig. S2)[13]. These findings indicated that both CD11b$^+$ and CD11b$^-$ IgA$^+$ cells could be classically categorized as PCs. This view was further supported by our finding that both populations expressed equal levels of Blimp1, a master transcription factor for PCs (Fig. 2c)[23].

The phenotypes of IgA$^+$ cells in the iLP differed from those of IgA$^+$ cells in the spleen. Splenic CD11b$^-$ IgA$^+$ cells exclusively had a memory phenotype (that is, B220$^+$, CD138$^-$, CD38^{int} and CD40^{hi}), whereas splenic CD11b$^+$ IgA$^+$ cells contained almost equal amounts of B220$^+$ CD138$^-$ CD38^{int} CD40^{hi} memory cells and B220$^-$ CD138$^+$ CD38^{hi} CD40^{low} PCs (Supplementary Fig. S3). These results indicated that CD11b$^+$ IgA$^+$ cells in the iLP were unique PCs that had an immunologically different status from splenic CD11b$^+$ IgA$^+$ cells.

Intestinal CD11b$^+$ IgA$^+$ PCs require PP lymphoid structure. CD11b$^+$ IgA$^+$ PCs expressed CD18 (Supplementary Fig. S4), which associates with CD11b and acts as a ligand for intercellular adhesion molecule-1 (ICAM-1)[24]. As ICAM-1 is an endothelial adhesion molecule that regulates cell trafficking[24,25], we considered that CD11b$^+$ IgA$^+$ PCs were recent emigrants from IgA-inductive tissues (for example, PPs and PerC) and had migrated into the iLP. To test this possibility, we employed FTY720 to inhibit the trafficking of IgA-committed B cells from PPs and PerC into the iLP. As we previously reported[11,13], FTY720 treatment reduced the numbers of intestinal IgA$^+$ PCs,


Figure 2 | Both CD11b$^+$ and CD11b$^-$ IgA$^+$ cells in the intestine are categorized as plasma cells. (a) Cells were purified by cell sorting from the iLP, and their morphology was examined by haematoxylin and eosin staining after cytospin. Data are representative of three independent experiments. **(b)** Cells were isolated from the iLP for the analysis of F4/80, CD11c and CCR3 expression on CD11b$^-$ IgA$^+$, CD11b$^+$ IgA$^+$ and CD11b$^+$ IgA$^-$ cells. Grey indicates isotype control. Similar results were obtained from three separate experiments. **(c)** Cells were isolated from the iLP for comparisons between CD11b$^+$ and CD11b$^-$ IgA$^+$ cells in terms of cell size (FSC) and density (SSC), and expression of CD19, B220, CD138, CD38, CD40 and Blimp1. Grey indicates isotype control. Similar results were obtained from five separate experiments.

– 218 –